

28 August 2018 NSX Announcement

Sales and Service Agreements with Beijing Youlian ENT Hospital

Beroni Group (NSX: BTG) is pleased to announce that its Chinese subsidiary, Beroni Biotechnology Co., Ltd ("Beroni") has signed a long-term product sales agreement ("Product Sales Agreement") and a short-term service agreement ("Service Agreement") with Beijing Youlian Ear, Nose and Throat Hospital ("Beijing Youlian"), a subsidiary of HNA Group which is a Chinese conglomerate headquartered in Haikou, Hainan with diversified business interests across aviation, tourism, logistics and financial services. The Product Sales Agreement allows Beijing Youlian to carry a series of Beroni's existing products at its hospital premises. Beroni believes its quit smoking aid, lung cleansing pills, air filtration systems, stem cell anti-aging treatment and susceptible gene detection services are complementary to patients seeking care at Beijing Youlian.

In addition to the product sales, Beijing Youlian has also engaged Beroni under the Service Agreement to arrange for tumor whole genome genetic testing, anti-aging beauty gene detection, and human whole genome sequencing. This service engagement will last until the end of calendar year 2018 and may be extended by mutual consent.

Beroni Group's Executive Chairman, Mr Jacky Zhang said: "Working with Beijing Youlian is yet another example of how Beroni can leverage its rapidly advancing networks in life science, environmental science, precision medicine, stem cell anti-cancer and anti-aging treatments. Partnership with Beijing Youlian is first of its kind for Beroni. I hope Beroni can work closely with Beijing Youlian to deliver results satisfactory to both parties and more importantly the people we cared for. A successful partnership will also see Beroni replicating this model in other parts of China and Japan."

For further information please contact:

Mr Jacky Zhang Mr Peter Wong

Executive Chairman Executive Director and CFO

Tel: +86 1851 6931 911 Tel: +61 423 727 580

E: <u>1710426553@qq.com</u> E: <u>pwong@asiainvest.com.au</u>

About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group is a Chinese biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group's overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.